Foghorn Therapeutics Inc. financial data

Symbol
FHTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
500 Technology Square, Suite 700, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
Mar 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 451 % -10.1%
Debt-to-equity -734 % -0.6%
Return On Equity 187 % -1.14%
Return On Assets -29.5 % +1.83%
Operating Margin -454 % -43.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 55.6M shares +30.6%
Common Stock, Shares, Outstanding 55.6M shares +31.5%
Entity Public Float 205M USD +2.4%
Common Stock, Value, Issued 6K USD +50%
Weighted Average Number of Shares Outstanding, Basic 54.9M shares +30.8%
Weighted Average Number of Shares Outstanding, Diluted 54.9M shares +30.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 22.6M USD -33.8%
Research and Development Expense 94.5M USD -13.8%
General and Administrative Expense 28.4M USD -12.4%
Operating Income (Loss) -103M USD +4.84%
Nonoperating Income (Expense) 16.1M USD +17.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -86.6M USD +8.05%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -86.6M USD +12%
Earnings Per Share, Basic -1.58 USD/shares +32.5%
Earnings Per Share, Diluted -1.58 USD/shares +32.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 55.5M USD -31%
Assets, Current 250M USD +3.92%
Operating Lease, Right-of-Use Asset 22.6M USD -24.4%
Other Assets, Noncurrent 68K USD -93.9%
Assets 284M USD -0.68%
Accounts Payable, Current 3.79M USD -39.5%
Employee-related Liabilities, Current 4.74M USD +9.09%
Accrued Liabilities, Current 8.53M USD -6.34%
Contract with Customer, Liability, Current 45.6M USD +32%
Liabilities, Current 67M USD +14.6%
Contract with Customer, Liability, Noncurrent 234M USD -12.6%
Operating Lease, Liability, Noncurrent 28.1M USD -23.2%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 330M USD -9.25%
Accumulated Other Comprehensive Income (Loss), Net of Tax 135K USD
Retained Earnings (Accumulated Deficit) -558M USD -18.4%
Stockholders' Equity Attributable to Parent -45.5M USD +41%
Liabilities and Equity 284M USD -0.68%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -29.3M USD +5.89%
Net Cash Provided by (Used in) Financing Activities 1.17M USD +1044%
Net Cash Provided by (Used in) Investing Activities 27.1M USD -8.17%
Common Stock, Shares Authorized 175M shares 0%
Common Stock, Shares, Issued 55.6M shares +31.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.08M USD +31.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 57.2M USD -30.3%
Deferred Tax Assets, Valuation Allowance 166M USD +16.4%
Deferred Tax Assets, Gross 174M USD +13.4%
Operating Lease, Liability 37.1M USD -17.6%
Payments to Acquire Property, Plant, and Equipment 101K USD -84.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -85.7M USD +10.1%
Lessee, Operating Lease, Liability, to be Paid 41.1M USD -19.7%
Operating Lease, Liability, Current 9.07M USD +6.45%
Lessee, Operating Lease, Liability, to be Paid, Year Two 10.8M USD +1.03%
Lessee, Operating Lease, Liability, to be Paid, Year One 10.8M USD +1.28%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.96M USD -34.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 11M USD +4.09%
Deferred Tax Assets, Operating Loss Carryforwards 14.5M USD +2201%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 25M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 8.47M USD -22%
Additional Paid in Capital 513M USD +29.7%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 3.12M USD -9.59%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%